Return of induction chemotherapy in head and neck squamous cell cancers: is this time different?
Mené en Chine sur 480 patients atteints d'un carcinome rhinopharyngé de stade III-IVB (âge : 18 à 59 ans ; durée médiane de suivi : 45 mois), cet essai multicentrique de phase III évalue, du point de vue de la survie sans échec à 3 ans et de la toxicité, l'intérêt d'ajouter à une chimioradiothérapie une chimiothérapie d'induction par cisplatine-fluorouracile-docétaxel
In locally advanced nasopharyngeal and other head and neck squamous cell cancers, cisplatin-based chemotherapy given concurrently with radiotherapy improves locoregional control and, to a lesser extent, distant control, leading to a survival benefit.1,2 However, induction chemotherapy given before radiotherapy has little to no effect on locoregional control and overall survival, although it can reduce distant metastases.1,2 Consequently, induction chemotherapy declined in popularity until the emergence of induction chemotherapy regimens containing docetaxel, cisplatin, and fluorouracil (TPF) sparked renewed interest.
The Lancet Oncology , commentaire, 2015